Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Inclusion Criteria

- Has histologically or cytologically confirmed diagnosis of locally advanced
unresectable or metastatic gastric or GEJ adenocarcinoma with known programmed cell
death ligand 1 (PD-L1) expression status

- Has HER2 negative cancer

- Male Participants must agree to use contraception during the treatment period and
through 180 days after the last dose of chemotherapy or through 120 days after the
last dose of pembrolizumab, whichever is greater, and must refrain from donating sperm
during this period

- Female Participants who are not pregnant, not breastfeeding, and at least one of the
following conditions applies: not a woman of childbearing potential (WOCBP) OR agrees
to use contraception during the treatment period and through 180 days after the last
dose of chemotherapy or through 120 days after the last dose of pembrolizumab,
whichever is greater

- Has measurable disease per RECIST 1.1 as assessed by investigator assessment

- Has provided archival tumor tissue sample or newly obtained core or excisional biopsy
of a tumor lesion not previously irradiated

- Has provided tumor tissue sample deemed adequate for PD-L1 biomarker analysis

- Has provided tumor tissue sample for microsatellite instability (MSI) biomarker
analysis

- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 3
days prior to the start of study intervention

- Has adequate organ function as demonstrated by laboratory testing within 10 days prior
to the start of study treatment

Exclusion Criteria

- Has squamous cell or undifferentiated gastric cancer

- Has had major surgery, open biopsy, or significant traumatic injury within 28 days
prior to randomization, anticipation of the need for major surgery during the course
of study intervention, or has not recovered adequately from the toxicity and/or
complications from previous surgery

- Has pre-existing peripheral neuropathy >Grade 1

- Is a WOCBP who has a positive urine pregnancy test within 72 hours prior to
randomization or treatment allocation

- Has had previous therapy for locally advanced, unresectable or metastatic gastric/GEJ
cancer. Participants may have received prior neoadjuvant or adjuvant therapy as long
as it was completed ≥6 months prior to randomization

- Has received prior therapy with an anti-PD-1, anti-PD-L1 or anti- PD-L2 agent or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX- 40, CD137)

- Has received prior systemic anticancer therapy including investigational agents within
4 weeks prior to randomization or has not recovered from all AEs due to any previous
therapies to ≤Grade 1 or baseline

- Has received prior radiotherapy within 2 weeks prior to study start or has not
recovered from all previous radiation-related toxicities, required corticosteroids,
and have not had radiation pneumonitis. A 1-week washout is permitted for palliative
radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease

- Has received a live vaccine within 30 days prior to the first dose of study treatment

- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study treatment

- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
or any other form of immunosuppressive therapy within 7 days prior to the first dose
of study treatment

- Has a known additional malignancy that is progressing or has required active treatment
within the past 5 years with the exception of basal cell carcinoma of the skin,
squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma,
cervical cancer in situ) that have undergone potentially curative therapy

- Has known active CNS metastases and/or carcinomatous meningitis

- Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients

- Has an active autoimmune disease that has required systemic treatment in past 2 years

- Has a history of (non-infectious) pneumonitis that required steroids or has current
pneumonitis

- Has an active infection requiring systemic therapy

- Has a known history of human immunodeficiency virus (HIV) infection

- Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]
reactive) or known active Hepatitis C virus (defined as Hepatitis C virus [HCV]
ribonucleic acid [RNA] detected qualitatively) infection

- Has a known history of active tuberculosis

- Has hypokalemia (serum potassium less than the lower limit of normal)

- Has hypomagnesemia (serum magnesium less than the lower limit of normal)

- Has hypocalcemia (serum calcium less than the lower limit of normal)

- Has a history or current evidence of any condition (eg, known deficiency of the enzyme
dihydropyrimidine dehydrogenase), therapy, or laboratory abnormality that might
confound the results of the study, interfere with the participant's participation for
the full duration of the study, or is not in the best interest of the participant to
participate, in the opinion of the treating investigator

- Has a known psychiatric or substance abuse disorder that would interfere with the
participant's ability to cooperate with the requirements of the study

- Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 180 days
after the last dose of chemotherapy or through 120 days after the last dose of
pembrolizumab, whichever is greater

- Has had an allogenic tissue/solid organ transplant

- Has a known severe hypersensitivity (≥ Grade 3) to any of the study chemotherapy
agents (including, but not limited to, infusional 5-fluorouracil or oral capecitabine)
and/or to any of their excipients

- For participants taking Cisplatin: has Grade ≥2 audiometric hearing loss (25 decibels
in two consecutive wave ranges)